Colossal Biosciences: Business Overview, Financials & Competitive Analysis

Colossal Biosciences Overview

Colossal Biosciences is an American biotechnology and genetic engineering company working to de-extinct several extinct animals, including the woolly mammoth, the Tasmanian tiger, the dire wolf, the dodo, the moa and the bluebuck. In 2025, the company reached a $10 billion valuation, becoming the first Texas-based startup to achieve decacorn status. The company combines ancient DNA reconstruction, CRISPR gene editing, and artificial reproductive technologies to advance both de-extinction and endangered species conservation.

Strategic Profile

The company develops genetic engineering and reproductive technology for conservation biology. The company has made breakthroughs such as generating the first de novo assembled mammoth genome and engineering elephant stem cells—advances that are already aiding endangered species like elephants. Its work on the woolly mammoth involves genetic adaptations that could rewild the tundra, slowing permafrost thaw and mitigating climate change.

Competitive Landscape

Colossal operates in a nascent de-extinction and conservation genomics space with limited direct competitors at commercial scale. Primary competitive pressures come from academic research labs (e.g., Harvard, UC Santa Cruz genetics programs), government agencies funding endangered species protection, and adjacent synthetic biology firms (e.g., Genentech, Intrexon/Precigen) with CRISPR capabilities. No established commercial de-extinction firms exist; Colossal holds first-mover advantage.

Industry Context

Colossal Biosciences operates in Biotechnology.

Key facts

Founded: 2021 · Headquarters: Dallas, US · Employees: 170+ (as of June 2026) · Revenue: N/A · Market cap: N/A (Private, $10.2B valuation as of January 2025)